ESTRO 2025 - Abstract Book

S2267

Interdisciplinary – Health economics & health services research

ESTRO 2025

Keywords: Integration of AI, MDT, Collaboration

682

Digital Poster Hypofractionation to ultrahypofractionation for prostate cancer: A 5.5-Year Review of Time and Cost Efficiency Ilya Lvovich, Lihi Shahar, Rimma Bahchevan, Salem Billan, Tomer Charas Radiotherapy Institute,Oncology Department, Rambam Health Care Center, Haifa, Israel Purpose/Objective: Radiation therapy is a well-established modality for the treatment of prostate cancer. Late technological advancements allow for better radiotherapy precision and efficiency. UHFRT (ultrahypofractionation radiotherapy) delivers high doses in few fractions with maximum precision, using advanced imaging for millimeter-level accuracy. The transition from HFRT (hypofractionation radiotherapy) to UHFRT represents a leap in prostate cancer treatment, offering fewer treatment sessions with enhanced precision and saves time for patients [1-3]. We aim to evaluate the transitioning from HFRT to UHFRT and its effect on treatment time and costs. Material/Methods: We retrospectively collected data for patients treated for prostate RT from MOSAIQ (Oncology Management System, version 2.83) on Elekta Infinity Linac. Treatment start and end times were collected from the User Audit Log. Single fraction defined as the time from we enter treatment by personal bar code, patient positioning and immobilization, treatment delivery and until we closed the treatment. UHFRT or HFRT were defined as per physician prescription; UHFRT course included 6 or 5 fractions, while HFRT course included 20 to 28 fractions[4]. Patients treated with RT post-prostatectomy were excluded. The average treatment time for each group calculated by analyzing data from 25 patients from both groups. Results: The study included 1,292 patients with prostate cancer, treated between January 2019 and September 2024.819 patients received HFRT and 473 received UHFRT. A significant increase in the use of UHFRT noted, with a 26% annual rise, culminating in a total increase of 200% from 44 to 132 cases [table 1.]. In contrast, HFRT had 15% annual increase, with a total increase of 93%. The distribution of patients treated with and without lymph nodes was 72% and 28%, respectively. Additionally, the average number of fractions required was 5.2 for UHFRT and 24.6 for HFRT. There was a notable trend of increasing UHFRT treatments from 31.4% to 41.6%, while HFRT treatments decreased from 68.6% to 58.4% from included patients, P-value of ≤ 0.005. The average treatment time was 18 minutes for UHFRT and 9 minutes for HFRT. The transition from HFRT to UHFRT resulted in reduced overall treatment time, increasing from 6,548 minutes to 17,356 minutes per year , which equals to treating an additional 27 to 78 HFRT patients [table 2.].